🇺🇸 FDA
Pipeline program

sotatercept, SOTATERCEPT, sotatercept, SOTATERCEPT

MK-7962-031

Phase 2 small_molecule active

Quick answer

sotatercept, SOTATERCEPT, sotatercept, SOTATERCEPT for Pulmonary Arterial Hypertension (PAH) is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Pulmonary Arterial Hypertension (PAH)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials